Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Whitehawk Therapeutics ( (WHWK) ) has shared an update.
On May 12, 2026, Whitehawk Therapeutics entered a securities purchase agreement with institutional and accredited investors for a private investment in public equity financing totaling $87.5 million. The deal covers 4,330,866 common shares at $3.92 and 17,991,021 pre-funded warrants at $3.9199 each, with the warrants exercisable at $0.0001 per share and subject to ownership caps.
The PIPE, expected to close on May 14, 2026, drew significant participation from existing specialist healthcare funds and company insiders committing $39.75 million, signaling confidence from key stakeholders. Whitehawk plans to use the proceeds alongside existing cash for working capital and to advance its ADC pipeline, which management says should materially extend its cash runway, while executives and directors agreed to 60-day lock-ups, and investors received resale registration rights.
The transaction is being executed as a private placement exempt from Securities Act registration, with Jefferies, Leerink Partners and several other banks acting as placement agents. Governance steps included approval of insider participation by independent board and audit committee members, aiming to mitigate conflicts of interest and support investor trust as the company funds ongoing clinical and development activities.
The most recent analyst rating on (WHWK) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Whitehawk Therapeutics stock, see the WHWK Stock Forecast page.
Spark’s Take on WHWK Stock
According to Spark, TipRanks’ AI Analyst, WHWK is a Neutral.
The score is primarily held back by weak financial performance—large ongoing losses, a sharp revenue decline, and significant cash burn—despite a low-debt balance sheet and improved gross margin. Technicals are moderately supportive with price above major moving averages and positive MACD, but valuation remains difficult to justify on earnings given the negative P/E and no indicated dividend.
To see Spark’s full report on WHWK stock, click here.
More about Whitehawk Therapeutics
Whitehawk Therapeutics, Inc. is a clinical-stage oncology company developing next-generation antibody drug conjugate cancer therapies. The firm applies advanced technologies to established tumor biology through a three-asset ADC portfolio in-licensed from WuXi Biologics under an exclusive global development and commercialization agreement.
Whitehawk focuses on addressing limitations of first-generation ADCs to provide improved treatment options for patients with difficult-to-treat cancers. Its programs target a global oncology market where differentiated ADCs are increasingly sought by clinicians, investors and strategic partners seeking durable, targeted cancer therapies.
The Nasdaq-listed company operates from Morristown, N.J., and collaborates with specialized investors active in biotechnology. This backing from sector-focused funds underscores Whitehawk’s positioning as an emerging player in the competitive ADC therapeutics landscape.
Average Trading Volume: 184,732
Technical Sentiment Signal: Hold
Current Market Cap: $193.9M
For detailed information about WHWK stock, go to TipRanks’ Stock Analysis page.